Emcure Pharmaceuticals Ltd. (EMCURE) Share Price Falls 3.14% Today; Stock Turns Top Decliner

Emcure Pharmaceuticals Ltd. traded at Rs 1,946.40, down 3.14% today, with a market capitalisation of Rs 38,055.53 crore, qualifying as a large-cap top decliner.

Emcure Pharmaceuticals Ltd. Share Price was at Rs 1,946.40 on 14 August 2026 at 12:17:14 PM IST, down Rs 63.05 or 3.14% from the previous close of Rs 2,009.45. With a market capitalisation of Rs 38,055.53 crore, the stock has drawn attention in Stock Market Today because the move was large enough to place it among the session’s top decliners under the workflow’s price-fall threshold screen.

The supplied data confirms the price event clearly: Emcure Pharmaceuticals Ltd. opened at Rs 2,015, which also marked the day’s high, and then moved lower to an intraday low of Rs 1,945 before trading near that zone. That intraday pattern points to persistent selling pressure rather than a brief dip, especially because the stock remained well below both the opening price and the previous close in midday trade.

The data establishes what happened, but it does not establish a company-specific catalyst for why the stock is falling today. Even so, Emcure Pharmaceuticals Ltd. Share Price Today is trending because the decline crossed the exact qualifying bar for its market-cap bracket, making it relevant for traders tracking Top Losers Today, price action and market movers in the Indian Stock Market.

For investors following Emcure Pharmaceuticals Ltd. Stock News, the key numbers to watch next are the intraday low of Rs 1,945, the ability of the stock to hold above that level, total traded volume of 75,775 shares across exchanges, turnover of Rs 0.43 crore, and how the company’s large market value compares with a much smaller sector benchmark set.

Emcure Pharmaceuticals Ltd. (EMCURE) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,946.4
Previous Close	Rs 2,009.45
Today's Change	Rs -63.05 (-3.14%)
Day Open	Rs 2,015
Day High	Rs 2,015
Day Low	Rs 1,945
Current Volume (BSE)	2,219
BSE Traded Volume	2,219
NSE Traded Volume	73,556
Combined NSE + BSE Volume	75,775
Turnover	Rs 0.43 crore
Market Capitalisation	Rs 38,055.53 crore
Market Cap Category	Large Cap

Emcure Pharmaceuticals Ltd. (EMCURE) traded at Rs 1,946.4. versus the previous close of Rs 2,009.45, a fall of 3.14%. The stock opened at Rs 2,015, reached Rs 2,015, touched Rs 1,945. Reported volume was 2,219.

Emcure Pharmaceuticals Ltd. (EMCURE) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 38,055.53 crore

Emcure Pharmaceuticals Ltd. Fundamental Analysis in the supplied dataset is led primarily by company size, trading context and sector positioning rather than a full balance-sheet or profit snapshot. Even with that narrower set of verified numbers, the market capitalisation of Rs 38,055.53 crore is an important anchor because it places the company far above the typical size seen in the healthcare benchmark basket supplied here.

That distinction matters. Market capitalisation indicates company size, not quality, but size can influence how investors interpret daily volatility. A 3.14% decline in a company valued at Rs 38,055.53 crore is a materially different market event from the same percentage move in a much smaller stock. It suggests the session’s weakness is meaningful enough to feature in Stocks in News even without any confirmed catalyst in the data.

From a trading context perspective, the stock’s turnover of Rs 0.43 crore and combined volume of 75,775 shares indicate that the decline happened with measurable market participation. The difference between the previous close of Rs 2,009.45 and the current price of Rs 1,946.40 also shows that the stock was not merely oscillating around a flat base; it established a lower price zone during the session.

For investors reading Emcure Pharmaceuticals Ltd. Share Price alongside broader stock analysis, the key fundamental takeaway is restraint. The available data supports close monitoring of market capitalisation, exchange participation and sector relative position, but it does not support any conclusion about earnings quality, balance-sheet strength or valuation multiples for the company itself. What it does support is that a large-cap healthcare stock has seen a verified price fall strong enough to warrant attention in Market News and stock updates. That makes sector and peer context especially useful for judging where the company sits within the listed healthcare universe.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Benchmark Median P/E	26.2x
Benchmark Average P/E	75.33x
Benchmark P/E Range	3.29x to 3,299.57x
Benchmark Median P/B	1.96x
Benchmark Median ROE	11.07%
Benchmark Median ROCE	13.35%
Company Market Capitalisation	Rs 38,055.53 crore
Benchmark Median Market Cap	Rs 141.55 crore

Emcure Pharmaceuticals Ltd. (EMCURE) is classified under sector: Healthcare.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

The sector backdrop shows why this move stands out. Emcure Pharmaceuticals Ltd. operates in Healthcare, and the supplied benchmark covers 196 companies in the same sector. Against that universe, the company’s market capitalisation is far larger than the sector’s benchmark market-cap averages and medians, making today’s decline notable in a relative-size context.

The Healthcare benchmark includes 196 companies, with a median market capitalisation of Rs 141.55 crore and an average of Rs 465.17 crore. The minimum in the benchmark is Rs 3.67 crore and the maximum is Rs 2,995.34 crore. Against those numbers, Emcure Pharmaceuticals Ltd. Market Cap of Rs 38,055.53 crore sits dramatically above even the benchmark maximum cited in the same-sector snapshot. That does not by itself indicate valuation strength or weakness, but it does underline how much larger the company is than the peer universe supplied for comparison.

The same benchmark also provides valuation and profitability context for the sector. Across 156 healthcare companies with available P/E data, the median P/E is 26.2 and the average is 75.33, with a range from 3.29 to 3,299.57. For 195 companies with P/B data, the median is 1.96 and the average is 2.65, ranging from -10.01 to 16.63. On profitability, the sector’s median ROE is 11.07% and average ROE is 15.46%, while median ROCE is 13.35% and average ROCE is 17.73%.

These sector numbers are useful because they frame the valuation and return profile typically seen in healthcare counters, especially pharmaceuticals and drugs names that dominate the benchmark list. In Univest’s view, this context matters for Emcure Pharmaceuticals Ltd. Share Price because the stock’s size makes any large single-day decline relevant beyond ordinary micro-cap volatility. The benchmark scope also shows that Healthcare is a broad listed universe rather than a narrow sample, which makes the comparison set more informative for investors tracking sector rotation, Bearish Stocks and Stocks Under Pressure.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,995.34	31.94	0.47	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,836.87	69.35	10.97	18.65	22.17
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,644.55	34.7	7.15	-2.6	16.92
Hikal Ltd.	HIKAL	2,619.52	0	2.24	15.22	16.15
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,605.37	45.02	1.73	-0.78	8.31

Emcure Pharmaceuticals Ltd. (EMCURE) has a market capitalisation of Rs 38,055.53 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

The peer data shows a healthcare comparison set made up mostly of pharmaceuticals and drugs companies, with one hospital and healthcare services name included. Emcure Pharmaceuticals Ltd. is not supplied with matching valuation ratios in this dataset, so the most direct verified comparison starts with market capitalisation and then uses peer P/E, P/B, ROE and ROCE figures to frame the broader landscape.

On size alone, Emcure Pharmaceuticals Ltd. stands apart. Its market capitalisation of Rs 38,055.53 crore is substantially above Dishman Carbogen Amcis at Rs 2,995.34 crore, Beta Drugs at Rs 2,836.87 crore, Dr Agarwals Eye Hospital at Rs 2,644.55 crore, Hikal at Rs 2,619.52 crore and Ind-Swift Laboratories at Rs 2,605.37 crore. It is also far above Panacea Biotec, Sai Parenteral's, Solara Active Pharma Sciences, Fredun Pharmaceuticals and Venus Remedies, all clustered between roughly Rs 2,214.91 crore and Rs 2,450.34 crore.

The peer profitability picture is mixed. Beta Drugs shows ROE of 18.65% and ROCE of 22.17%, which are among the strongest in the list. Hikal posts ROE of 15.22% and ROCE of 16.15%, while Solara shows ROE of 17.23% and ROCE of 15.34%. At the weaker end, Dishman Carbogen Amcis has ROE of -2.89% and ROCE of -0.26%, and Dr Agarwals Eye Hospital shows ROE of -2.6% despite ROCE of 16.92%. Ind-Swift Laboratories has ROE of -0.78% and ROCE of 8.31%.

Valuation multiples also span a wide range. P/E values include 19.99 for Venus Remedies, 31.94 for Dishman Carbogen Amcis, 34.7 for Dr Agarwals Eye Hospital, 45.02 for Ind-Swift Laboratories, 56.53 for Fredun Pharmaceuticals, 69.35 for Beta Drugs and 174.73 for Sai Parenteral's. P/B ranges from 0.47 for Dishman Carbogen Amcis to 10.97 for Beta Drugs. For Univest readers, this wide spread reinforces that Healthcare peer analysis needs to be selective: the listed universe contains both low-multiple and high-multiple names, as well as firms with negative and positive return ratios. Emcure Pharmaceuticals Ltd. Share Price therefore deserves to be tracked with size context first and peer metrics second.

Why Investors Are Watching Emcure Pharmaceuticals Ltd.

Investors are watching Emcure Pharmaceuticals Ltd. Share Price because a large-cap healthcare stock has recorded a verified single-day fall large enough to qualify under the threshold-based decliner screen. In a market where many sharp moves come from smaller counters, today’s decline stands out simply because of the company’s scale and the intraday pattern visible in the supplied data.

• Price action: The stock fell 3.14% to Rs 1,946.40 from Rs 2,009.45, after opening at Rs 2,015 and slipping to a low of Rs 1,945.
• Market-cap relevance: With a market capitalisation of Rs 38,055.
• Trading activity: Total volume reached 75,775 shares, with 73,556 on NSE and 2,219 on BSE, while turnover stood at Rs 0.43 crore.
• Sector position: The company’s size is well above the 196-company healthcare benchmark, whose average market cap is Rs 465.17 crore and maximum is Rs 2,995.34 crore.
• Peer context: The peer set shows wide dispersion in P/E, P/B, ROE and ROCE, highlighting that relative analysis in healthcare remains important.

What investors may monitor next is straightforward: whether the stock continues to hold near the day low or stabilises above it, whether turnover builds beyond midday levels, and how Emcure Pharmaceuticals Ltd. Stock News develops through the session. On Univest, this combination of price action, market cap and sector context is what keeps the stock in focus without turning the move into a directional call.

About Emcure Pharmaceuticals Ltd.

Emcure Pharmaceuticals Ltd. is placed in the Healthcare sector in the supplied data. Within the available comparison universe, most relevant listed names fall under Pharmaceuticals & Drugs, while one peer operates in Hospital & Healthcare Services. That positioning matters because investors typically analyse such companies through a mix of sector valuation, profitability ratios and market-cap context rather than through price action alone.

The company is identified in the market under the symbol EMCURE. For search-oriented readers following Emcure Pharmaceuticals Ltd. Latest News, the current event is being tracked as a price-fall threshold hit rather than a results release or a corporate announcement-based move. The dataset classifies it under the top losers screener, which places the company among the notable Stocks Falling Today.

The best verified business context available here therefore comes from industry placement and relative scale. Emcure Pharmaceuticals Ltd. belongs to a Healthcare market where the benchmark covers 196 companies, many of them pharmaceuticals and drugs businesses. Yet its market capitalisation of Rs 38,055.53 crore is larger than the biggest company value shown within that same benchmark list. That makes Emcure Pharmaceuticals Ltd. Share Price especially relevant for investors who follow larger healthcare names and want to separate routine intraday noise from more meaningful market moves. Univest presents that context so users can assess the stock within the broader listed healthcare ecosystem.

Track Emcure Pharmaceuticals Ltd. Share Price on Univest

Use Emcure Pharmaceuticals Ltd. (EMCURE) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Users tracking Emcure Pharmaceuticals Ltd. Share Price can use Univest to follow live price movement, intraday range, previous close, market capitalisation and exchange-wise trading activity in one place. For a stock that has entered the top decliner screen, that consolidated view helps users compare the latest price action with broader market behaviour.

Univest also helps readers monitor sector context, peer metrics, 52-week levels when available, and evolving market insights around Healthcare counters. If you are following Emcure Pharmaceuticals Ltd. Share Price Today, Univest provides a practical way to stay updated on stock analysis, shareholding pattern where available, and comparative valuation snapshots without turning a single-session move into an investment recommendation.

Frequently Asked Questions

What is Emcure Pharmaceuticals Ltd. Share Price today?

Ans. Emcure Pharmaceuticals Ltd. Share Price was Rs 1,946.40 at 12:17:14 PM IST on 14 August 2026. The stock was down Rs 63.05 from the previous close of Rs 2,009.45, making it one of the session’s notable decliners.

Why is Emcure Pharmaceuticals Ltd. Share Price in focus today?

Ans. The stock is in focus because it fell 3.14% in a single session and qualified under the large-cap price-fall threshold screen. The supplied data confirms the decline, though it does not establish a company-specific catalyst for the move.

How much did Emcure Pharmaceuticals Ltd. stock fall today?

Ans. Emcure Pharmaceuticals Ltd. stock declined by Rs 63.05, or 3.14%, versus its previous close. It moved from Rs 2,009.45 to Rs 1,946.40, which was close to the intraday low of Rs 1,945 at the time of writing.

What were the day high and day low for Emcure Pharmaceuticals Ltd.?

Ans. The stock’s day high was Rs 2,015 and its day low was Rs 1,945. Notably, the opening price was also Rs 2,015, showing that the stock weakened after the open and stayed near the lower end.

What does today’s price action indicate for Emcure Pharmaceuticals Ltd.?

Ans. Today’s price action shows weakness through the session, because the stock opened at the day’s high and then traded down toward the low. That pattern suggests sustained selling pressure rather than a brief early dip followed by recovery.

What is the market capitalisation of Emcure Pharmaceuticals Ltd.?

Ans. Emcure Pharmaceuticals Ltd. had a market capitalisation of Rs 38,055.53 crore in the supplied data. That places it in the Large Cap category and makes a 3.14% same-day decline more notable in market context.

How much volume was traded in Emcure Pharmaceuticals Ltd. today?

Ans. Total traded volume stood at 75,775 shares, including 73,556 shares on NSE and 2,219 shares on BSE. The reported turnover was Rs 0.43 crore, giving a useful picture of participation during the session’s decline.

How does Emcure Pharmaceuticals Ltd. compare with the healthcare sector on size?

Ans. The company’s market capitalisation of Rs 38,055.53 crore is far above the healthcare benchmark average of Rs 465.17 crore and median of Rs 141.55 crore. It also exceeds the benchmark maximum company value of Rs 2,995.34 crore.

What does the healthcare sector benchmark show around valuations and returns?

Ans. In the supplied healthcare benchmark, median P/E is 26.2 and average P/E is 75.33. Median ROE is 11.07% and median ROCE is 13.35%, showing a broad spread of valuation and profitability across 196 companies.

Which peers are included in the comparison for Emcure Pharmaceuticals Ltd.?

Ans. The supplied peer set includes Dishman Carbogen Amcis, Beta Drugs, Dr Agarwals Eye Hospital, Hikal, Ind-Swift Laboratories, Panacea Biotec, Sai Parenteral's, Solara Active Pharma Sciences, Fredun Pharmaceuticals and Venus Remedies, all within the Healthcare space.